SpectraCure decides on Set-off Issue

The Board of Directors has, on the basis of authorization at the annual general meeting (AGM) on 18 May 2016, decided to issue 2 493 780 units at the same rate as in the recently completed rights issue (0.80 SEK) for compensation equivalent to SEK 1 995 024 to advisors in accordance with contract. The aim of the set-off issue is to increase SpectraCures financial leeway by not burdening the company's liquidity with advisers compensation in the above mentioned rights issue. In this context, the company has made an objective assessment that the issue is not detrimental to the company's shareholders and that there is marketability. The subscribers are as follows:

  • G&W fondkommission: 997 512 SEK which is equivalent to 1 246 890 units
  • Göteborg Corporate Finance: 598 508 SEK which is equivalent to 748 135 units
  • Corale AB: 399 004 SEK, equivalent to 498 755 units

The share capital will increase by 249 378 SEK equivalent to 1 995 024 SEK from 5 409 774 SEK to 5 659 152 kr. The total number of shares will, after the registration of the set-off issue with the Swedish companies Agency, amount to 56 591 520. G&W Fondkommission and Göteborg Corporate Finance have served as financial advisors in connection with the transactions.

For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was foundd in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.

Read as PDF.

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope